Medtronic must be serious about increasing its penetration in the diabetes management market. The company recently unveiled a collaboration with Samsung related to the development of mobile diabetes apps for Samsung technology along with two other pieces of diabetes related news.

Brian Buntz

Medtronic recently announced FDA clearance for its MiniMed Connect technology, which enables smartphone users to view data from the firm's CGM and insulin pumps.

The company will be working with Samsung to develop new applications for the MiniMed Connect platform, which is a roughly a thumb-sized unit that harvests data from Medtronic's MiniMed insulin pump and select CGM devices. Once the data is gathered, the platform can deliver it to a mobile app or an online portal where patients and caregivers can access it. Alarms can be triggered when glucose levels are out of range.

"We are excited to partner with Medtronic to develop diabetes management solutions that produce positive change and greater autonomy for people living with diabetes," David Rhew, MD, chief medical officer for Samsung Electronics America noted in a statement.

Finally, the company shared more details related to its partnership with the startup Glooko, the maker of an FDA-cleared diabetes management software for smartphones.

Earlier in the year, Glooko announced that it had won $16.5 million in Series B funding and that Medtronic was among the investors who had ponied up cash in the round.

Learn more about the medical device industry at MD&M East in New York City, June 9-11, 2015.